Aripiprazole

Generic Name
Aripiprazole
Brand Names
Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva
Drug Type
Small Molecule
Chemical Formula
C23H27Cl2N3O2
CAS Number
129722-12-9
Unique Ingredient Identifier
82VFR53I78
Background

Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A ...

Indication

Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation as...

Associated Conditions
Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode
Associated Therapies
Monotherapy
Clinical Trials
Related News

Aripiprazole Oral Acceptability Trial

Phase 3
Completed
Conditions
Schizophrenia
Interventions
Drug: Aripiprazole
First Posted Date
2005-01-13
Last Posted Date
2013-11-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
59
Registration Number
NCT00101569
Locations
🇺🇸

Local Institution, Falls Church, Virginia, United States

Study of Aripiprazole in Patients With Acute Bipolar Mania

First Posted Date
2004-11-22
Last Posted Date
2013-11-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
615
Registration Number
NCT00097266
Locations
🇿🇦

Local Institution, Berea, Kwa Zuluu Natal, South Africa

Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia

Phase 3
Completed
Conditions
Dementia
Alzheimer's Disease
Interventions
Drug: Aripiprazole
Drug: Placebo
First Posted Date
2004-11-09
Last Posted Date
2013-11-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
125
Registration Number
NCT00095719
Locations
🇺🇸

Local Institution, Midvale, Utah, United States

Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease

Phase 4
Completed
Conditions
Parkinson's Disease
Psychoses
Interventions
Drug: aripiprazole
First Posted Date
2004-11-09
Last Posted Date
2013-11-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
50
Registration Number
NCT00095810
Locations
🇺🇸

Local Institution, Albany, New York, United States

Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

First Posted Date
2004-11-08
Last Posted Date
2013-11-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
300
Registration Number
NCT00095524
Locations
🇬🇧

Local Institution, Birmingham, West Midlands, United Kingdom

Aripiprazole in Patients With Acute Mania

Phase 3
Completed
Conditions
Bipolar Disorder
First Posted Date
2004-11-08
Last Posted Date
2013-11-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
615
Registration Number
NCT00095511
Locations
🇺🇸

Local Institution, Arlington, Virginia, United States

🇺🇸

Local Institition, Shreveport, Louisiana, United States

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

Phase 3
Completed
Conditions
Bipolar I Disorder
Interventions
Drug: Placebo
Drug: Aripiprazole
First Posted Date
2004-10-19
Last Posted Date
2013-11-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
650
Registration Number
NCT00094432
Locations
🇺🇸

Local Institution, Charleston, West Virginia, United States

Assessment of Interactions Between Methamphetamine and Aripiprazole - 1

First Posted Date
2004-08-06
Last Posted Date
2017-01-11
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Target Recruit Count
17
Registration Number
NCT00089440
Locations
🇺🇸

New York University, School of Medicine, New York, New York, United States

🇺🇸

UCLA Integrated Substance Abuse Program, Los Angeles, California, United States

Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia

Phase 4
Completed
Conditions
Schizophrenia
First Posted Date
2004-07-21
Last Posted Date
2007-07-18
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
560
Registration Number
NCT00088049
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Salt Lake City, Utah, United States

Study of Aripiprazole in Subjects With Alcoholism

Phase 4
Completed
Conditions
Alcoholism
Interventions
Drug: Placebo
Drug: Aripiprazole
First Posted Date
2004-05-04
Last Posted Date
2013-11-11
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
400
Registration Number
NCT00082199
Locations
🇺🇸

Local Institution, Milwaukee, Wisconsin, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy